Business
Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® I...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlbertaSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that its President and Chief Executive Officer, Matt Coffey, Ph.D., MBA, was presented with the Scientific Achievement and Innovation Award by BioAlberta, the province's life sciences industry association. BioAlberta recognized several industry leaders for their innovation and achievements during its Annual AGM, Awards Gala and Industry Showcase at the Westin Edmonton.\"I am honored to receive this recognition from BioAlberta for my work in oncolytic viruses, which started a little more than twenty years ago at the University of Calgary,\" said Dr. Coffey. \"This entire drug class has come a long way in the last two decades and I'm proud to have been a part of that, and the learnings this drug class has brought about. We learned about pelareorep's ability to double overall survival in hormone receptor-positive metastatic breast cancer patients and we continue to study it in this setting, as well as in pancreatic cancer and multiple myeloma. Most importantly, we've learned about the ability of oncolytic viruses to wake up the immune system. There are amazing immunotherapy treatments, such as checkpoint inhibitors, that invigorate the immune system and can provide significant benefits for patients, but today they work in only one-in-five patients. By waking the immune system, oncolytic viruses have the potential to significantly increase the effectiveness of checkpoint inhibitors and have a positive effect on patients' lives.\"About PelareorepPelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.About Oncolytics Biotech Inc.Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered imm...